Keros Therapeutics closed at $10.83 on Nov 4, unchanged, 50.4% below its 52-week closing high. Volume of 128.2K shares was 0.80× its 20-day average (below normal).
Split-adjusted performance: -1.6% over one month, -8.1% over six months, -28.8% over one year.
Short interest was 1.1M shares at the Oct 15 settlement, down 1.1% from the prior report (6.2% of float, 6.5 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| KROSKeros Therapeutics | $10.83 | 0.00% | −8.1% | −100.0% | — | — | $214.7M | |
| EVMNEvommune | $6.04 | +1.68% | −74.7% | — | — | — | $219.2M | Compare |
| ELDNEledon Pharmaceuticals | $2.70 | +3.05% | −28.9% | — | — | — | $219.4M | Compare |
| ADCTADC Therapeutics SA | $1.72 | +10.97% | −55.4% | +2.2% | −86.1% | — | $219.6M | Compare |
| RNACCartesian Therapeutics | $6.82 | +6.40% | −18.2% | −100.0% | — | — | $206.3M | Compare |
| NATRNature's Sunshine Products | $12.84 | +6.38% | −51.1% | +1.9% | 3.0% | 12.5 | $225.9M | Compare |
| SIGASIGA Technologies | $3.15 | +1.29% | −33.0% | −49.5% | 30.4% | — | $226.3M | Compare |
| UPBUpstream Bio | $3.70 | +9.14% | −59.7% | −17.5% | −5136.1% | — | $202.7M | Compare |
| NAGENiagen Bioscience | $2.52 | +6.78% | −49.3% | −4.3% | 3.2% | 12.5 | $199.4M | Compare |
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
